Reuben Ben-David, Francesco Pellegrino, Reza Mehrazin, Joel Thomas, Jack Geduldig, Sarah Lidagoster, Evan B. Garden, Kyrollis Attalla, Ahmed Eraky, Paolo Zaurito, Marco Moschini, Alberto Briganti, Francesco Montorsi, John P. Sfakianos, Peter Wiklund
To assess 30- and 90-day postoperative complication rates in patients who underwent robot-assisted radical cystectomy (RARC) after receiving novel immunotherapy-based neoadjuvant treatment.
{"title":"Immunotherapy-based neoadjuvant treatment and complication rates after radical cystectomy","authors":"Reuben Ben-David, Francesco Pellegrino, Reza Mehrazin, Joel Thomas, Jack Geduldig, Sarah Lidagoster, Evan B. Garden, Kyrollis Attalla, Ahmed Eraky, Paolo Zaurito, Marco Moschini, Alberto Briganti, Francesco Montorsi, John P. Sfakianos, Peter Wiklund","doi":"10.1111/bju.16662","DOIUrl":"https://doi.org/10.1111/bju.16662","url":null,"abstract":"To assess 30- and 90-day postoperative complication rates in patients who underwent robot-assisted radical cystectomy (RARC) after receiving novel immunotherapy-based neoadjuvant treatment.","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"25 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143021109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Juho Pylväläinen, Kirsi Talala, Jani Raitanen, Antti Rannikko, Anssi Auvinen
To assess the association between prostate-specific antigen (PSA) density (PSAD) and prostate cancer mortality after a benign result on systematic transrectal ultrasonography (TRUS)-guided prostate biopsy.
{"title":"Association of prostate-specific antigen density with prostate cancer mortality after a benign systematic prostate biopsy result","authors":"Juho Pylväläinen, Kirsi Talala, Jani Raitanen, Antti Rannikko, Anssi Auvinen","doi":"10.1111/bju.16641","DOIUrl":"https://doi.org/10.1111/bju.16641","url":null,"abstract":"To assess the association between prostate-specific antigen (PSA) density (PSAD) and prostate cancer mortality after a benign result on systematic transrectal ultrasonography (TRUS)-guided prostate biopsy.","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"81 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142992062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sebastian Kälble, Simon U. Engelmann, Hannah Schrutz, Florian Zeman, Emily Rinderknecht, Maximilian Haas, Christoph Pickl, Christopher Goßler, Yushan Yang, Stefan Denzinger, Maximilian Burger, Johannes Bründl, Roman Mayr
To assess the feasibility of trial recruitment and confirm that retroperitoneal robotic partial nephrectomy (RRPN) has the same oncological efficacy as transperitoneal robotic partial nephrectomy (TRPN), with time advantages and less peri-operative morbidity, in a randomised controlled trial (RCT).
{"title":"Randomised controlled feasibility trial of retroperitoneal vs transperitoneal robot-assisted partial nephrectomy: the ROPARN study","authors":"Sebastian Kälble, Simon U. Engelmann, Hannah Schrutz, Florian Zeman, Emily Rinderknecht, Maximilian Haas, Christoph Pickl, Christopher Goßler, Yushan Yang, Stefan Denzinger, Maximilian Burger, Johannes Bründl, Roman Mayr","doi":"10.1111/bju.16653","DOIUrl":"https://doi.org/10.1111/bju.16653","url":null,"abstract":"To assess the feasibility of trial recruitment and confirm that retroperitoneal robotic partial nephrectomy (RRPN) has the same oncological efficacy as transperitoneal robotic partial nephrectomy (TRPN), with time advantages and less peri-operative morbidity, in a randomised controlled trial (RCT).","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"10 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142992061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Aikaterini Eleftheriadou, James Aljoe, Matthew Deacon, Vishwas Iyer, Nimalan Arumainayagam
Click on the article title to read more.
点击文章标题阅读更多内容。
{"title":"Rethinking routine histological analysis of transurethral resection of the prostate tissue samples: cost, relevance, and patient impact","authors":"Aikaterini Eleftheriadou, James Aljoe, Matthew Deacon, Vishwas Iyer, Nimalan Arumainayagam","doi":"10.1111/bju.16649","DOIUrl":"https://doi.org/10.1111/bju.16649","url":null,"abstract":"Click on the article title to read more.","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"49 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142991637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jennifer Xu, Matthew Alberto, Dixon Woon, Damien Bolton, Joseph Ischia
ObjectivesTo summarise the impact of the coronavirus disease 2019 (COVID‐19) pandemic on urological practice globally with a focus on Australian initiatives, as the pandemic resulted in radical changes in healthcare infrastructure and policies.MethodsWe conducted a literature review of the Medical Literature Analysis and Retrieval System Online (MEDLINE), Excerpta Medica dataBASE (EMBASE) and Web of Science medical databases. The key terms used to conduct our search algorithm comprised of ‘COVID’, ‘wait list or wait time or delay’, ‘urology’, ‘surgery’ and ‘outcomes’, and generated 231 articles. Abstracts were reviewed for relevance and 40 studies selected for full‐text review. Society position statements and government level press release statements were identified through citation tracking and additionally included.Results/discussionThe halt on elective surgical services during the pandemic was deemed necessary to curb infection rates and conserve healthcare resources. However, it resulted in extended wait times and large surgical backlogs with major downstream effects. Australia fared favourably with regards to infection rates compared to international populations consequent upon strict border control, vaccine mandates, and stringent lockdowns. However, similar trends were noted in both oncological and non‐oncological urology service reduction, resulting in significant concerns regarding the long‐term sequelae of delayed surgery and missed appointments upon patient clinical outcome. Initiatives including collaborative partnerships between public and private hospital sectors, government‐funded programmes and adoption of telehealth were successfully established as part of Australia's efforts to stabilise our healthcare system in response to the pandemic.ConclusionAustralia's pandemic efforts have highlighted the escalating imbalance between increasing demand from a growing and ageing population on an already over‐burdened system with finite resources. The additional strain of managing post‐COVID‐19 pandemic fallout in this context provides further challenges for clinicians and healthcare administrators alike. Collaboration by all stakeholders must continue in order to seek innovative solutions to maximise efficiency of healthcare service utilisation, so that quality universal healthcare provision may continue in the future.
目的总结2019年冠状病毒病（COVID - 19）大流行对全球泌尿外科实践的影响，重点关注澳大利亚的举措，因为大流行导致医疗基础设施和政策发生了根本性变化。方法对医学文献分析与检索系统（MEDLINE）、医学摘录数据库（EMBASE）和Web of Science医学数据库进行文献综述。用于执行我们搜索算法的关键术语包括“COVID”、“等待名单或等待时间或延迟”、“泌尿外科”、“手术”和“结果”，并生成了231篇文章。对摘要进行相关性审查，并选择40项研究进行全文审查。通过引文跟踪识别社会立场声明和政府层面的新闻稿声明，并将其附加在内。结果/讨论大流行期间暂停选择性手术服务被认为是控制感染率和节约医疗资源的必要措施。然而，这导致了等待时间延长和大量手术积压，并产生了主要的下游影响。由于严格的边境管制、疫苗授权和严格的封锁，与国际人口相比，澳大利亚在感染率方面表现良好。然而，在肿瘤和非肿瘤泌尿外科服务减少中也发现了类似的趋势，这导致了对延迟手术和错过预约对患者临床结果的长期后遗症的重大关注。作为澳大利亚稳定医疗体系以应对疫情努力的一部分，包括公立和私立医院部门之间的合作伙伴关系、政府资助的项目和采用远程医疗在内的举措已经成功确立。澳大利亚的疫情防控工作凸显了日益增长的人口和老龄化人口在资源有限、负担过重的系统中不断增加的需求之间不断加剧的不平衡。在这种背景下，管理COVID - 19后大流行后果的额外压力为临床医生和医疗保健管理人员带来了进一步的挑战。所有利益攸关方必须继续合作，以寻求创新的解决方案，最大限度地提高医疗保健服务的利用效率，以便在未来继续提供高质量的全民医疗保健。
{"title":"The COVID‐19 pandemic and Urology – reflecting on successful initiatives and lessons in Australia","authors":"Jennifer Xu, Matthew Alberto, Dixon Woon, Damien Bolton, Joseph Ischia","doi":"10.1111/bju.16652","DOIUrl":"https://doi.org/10.1111/bju.16652","url":null,"abstract":"ObjectivesTo summarise the impact of the coronavirus disease 2019 (COVID‐19) pandemic on urological practice globally with a focus on Australian initiatives, as the pandemic resulted in radical changes in healthcare infrastructure and policies.MethodsWe conducted a literature review of the Medical Literature Analysis and Retrieval System Online (MEDLINE), Excerpta Medica dataBASE (EMBASE) and Web of Science medical databases. The key terms used to conduct our search algorithm comprised of ‘COVID’, ‘wait list or wait time or delay’, ‘urology’, ‘surgery’ and ‘outcomes’, and generated 231 articles. Abstracts were reviewed for relevance and 40 studies selected for full‐text review. Society position statements and government level press release statements were identified through citation tracking and additionally included.Results/discussionThe halt on elective surgical services during the pandemic was deemed necessary to curb infection rates and conserve healthcare resources. However, it resulted in extended wait times and large surgical backlogs with major downstream effects. Australia fared favourably with regards to infection rates compared to international populations consequent upon strict border control, vaccine mandates, and stringent lockdowns. However, similar trends were noted in both oncological and non‐oncological urology service reduction, resulting in significant concerns regarding the long‐term sequelae of delayed surgery and missed appointments upon patient clinical outcome. Initiatives including collaborative partnerships between public and private hospital sectors, government‐funded programmes and adoption of telehealth were successfully established as part of Australia's efforts to stabilise our healthcare system in response to the pandemic.ConclusionAustralia's pandemic efforts have highlighted the escalating imbalance between increasing demand from a growing and ageing population on an already over‐burdened system with finite resources. The additional strain of managing post‐COVID‐19 pandemic fallout in this context provides further challenges for clinicians and healthcare administrators alike. Collaboration by all stakeholders must continue in order to seek innovative solutions to maximise efficiency of healthcare service utilisation, so that quality universal healthcare provision may continue in the future.","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"70 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142989862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"February's reviewers of the month","authors":"","doi":"10.1111/bju.16634","DOIUrl":"https://doi.org/10.1111/bju.16634","url":null,"abstract":"Click on the article title to read more.","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"121 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142991464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Outcomes of prostate cancer treatments","authors":"","doi":"10.1111/bju.16633","DOIUrl":"https://doi.org/10.1111/bju.16633","url":null,"abstract":"Click on the article title to read more.","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"140 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142991465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alice Yu, Patrick J. Hensley, Heather L. Huelster, Austin Martin, Aaron Potrezke, Jonathan Pham, Jay D. Raman, Maximilian Pallauf, Nirmish Singla, Andrew Katims, Jonathan Coleman, Vitaly Margulis, Surena F. Matin, Philippe E. Spiess
ObjectivesTo evaluate the benefit of neoadjuvant chemotherapy (NAC) for patients with high‐risk upper tract urothelial carcinoma (UTUC) using a large, well‐curated multi‐institutional database.Patients and MethodsThis study was a multi‐institutional retrospective analysis conducted by the UTUC Collaborative Network (UCAN), combining data from 2276 patients with UTUC who underwent radical nephroureterectomy at seven high‐volume tertiary care centres in the United States. The UCAN data were analysed to evaluate the impact of response to NAC on survival outcomes in patients with UTUC.ResultsA total of 378 patients in the UCAN database underwent NAC. On final surgical pathology, 101 patients (26.8%) had ≤ypT1N0 disease and were defined as NAC treatment responders. Patients who responded to NAC had significantly longer overall survival (OS) and progression‐free survival (PFS) compared to non‐responders. At 5 years post‐surgery, 81.5% of responders were alive compared to 59.8% of non‐responders. The median OS and PFS times among non‐responders were 7.0 years (95% confidence interval [CI] 5.6–9.7) and 6.0 years (95% CI 4.6–9.3) respectively, while the median OS and PFS were not reached among responders. Limitations of this study include its retrospective design, heterogeneity in chemotherapy regimens, and the absence of clearly defined patient selection criteria for treatment.ConclusionThese data suggest that NAC can play a pivotal role in the treatment of well‐selected UTUC patients who respond positively. Non‐responders had clearly inferior outcomes. More work is needed to find predictors of response which can improve patient selection.
目的通过一个大型、精心整理的多机构数据库，评估新辅助化疗（NAC）对高危上尿路上皮癌（UTUC）患者的益处。患者和方法本研究是由UTUC协作网络（UCAN）进行的一项多机构回顾性分析，结合了美国7个高容量三级医疗中心接受根治性肾输尿管切除术的2276例UTUC患者的数据。对UCAN数据进行分析，以评估NAC应答对UTUC患者生存结局的影响。结果UCAN数据库中共有378例患者接受了NAC。在最终手术病理中，101例（26.8%）患者的疾病≤ypT1N0，被定义为NAC治疗应答者。与无反应者相比，对NAC有反应的患者有更长的总生存期（OS）和无进展生存期（PFS）。术后5年，81.5%的应答者存活，而59.8%的无应答者存活。无应答者的中位OS和PFS时间分别为7.0年（95%可信区间[CI] 5.6-9.7）和6.0年（95% CI 4.6-9.3），而应答者的中位OS和PFS未达到。本研究的局限性包括其回顾性设计，化疗方案的异质性，以及缺乏明确定义的患者选择治疗标准。结论：这些数据表明，NAC可以在筛选良好的UTUC患者的治疗中发挥关键作用。无应答者的预后明显较差。需要做更多的工作来发现反应的预测因子，从而改善患者的选择。
{"title":"Response to neoadjuvant chemotherapy leads to better survival outcomes in upper tract urothelial carcinoma","authors":"Alice Yu, Patrick J. Hensley, Heather L. Huelster, Austin Martin, Aaron Potrezke, Jonathan Pham, Jay D. Raman, Maximilian Pallauf, Nirmish Singla, Andrew Katims, Jonathan Coleman, Vitaly Margulis, Surena F. Matin, Philippe E. Spiess","doi":"10.1111/bju.16655","DOIUrl":"https://doi.org/10.1111/bju.16655","url":null,"abstract":"ObjectivesTo evaluate the benefit of neoadjuvant chemotherapy (NAC) for patients with high‐risk upper tract urothelial carcinoma (UTUC) using a large, well‐curated multi‐institutional database.Patients and MethodsThis study was a multi‐institutional retrospective analysis conducted by the UTUC Collaborative Network (UCAN), combining data from 2276 patients with UTUC who underwent radical nephroureterectomy at seven high‐volume tertiary care centres in the United States. The UCAN data were analysed to evaluate the impact of response to NAC on survival outcomes in patients with UTUC.ResultsA total of 378 patients in the UCAN database underwent NAC. On final surgical pathology, 101 patients (26.8%) had ≤ypT1N0 disease and were defined as NAC treatment responders. Patients who responded to NAC had significantly longer overall survival (OS) and progression‐free survival (PFS) compared to non‐responders. At 5 years post‐surgery, 81.5% of responders were alive compared to 59.8% of non‐responders. The median OS and PFS times among non‐responders were 7.0 years (95% confidence interval [CI] 5.6–9.7) and 6.0 years (95% CI 4.6–9.3) respectively, while the median OS and PFS were not reached among responders. Limitations of this study include its retrospective design, heterogeneity in chemotherapy regimens, and the absence of clearly defined patient selection criteria for treatment.ConclusionThese data suggest that NAC can play a pivotal role in the treatment of well‐selected UTUC patients who respond positively. Non‐responders had clearly inferior outcomes. More work is needed to find predictors of response which can improve patient selection.","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"253 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142988465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Robotic surgery: turning proficiency to independence in modern times","authors":"Kamran Haq, Bhavan Prasad Rai","doi":"10.1111/bju.16656","DOIUrl":"https://doi.org/10.1111/bju.16656","url":null,"abstract":"Click on the article title to read more.","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"7 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142988488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jessica A. Paynter, Zakary Doherty, Kirby R. Qin, David Pilcher, Janelle Brennan
ObjectivesTo examine demographics and in‐hospital outcomes for patients admitted to Australian intensive care units (ICUs) following cystectomy of the urinary bladder. Additionally, to compare outcomes between metropolitan and rural hospitals.Patients and MethodsA retrospective cohort analysis was undertaken of all adult patients admitted to participating Australian ICUs (Australian and New Zealand Intensive Care Society Adult Patient Database) following cystectomy/cystoprostatectomy between January 2011 and December 2021. The primary outcome was in‐hospital mortality. Secondary outcomes were ICU and hospital length of stay.ResultsOver the 10‐year period, 3376 adult patients were admitted to 135 Australian ICUs after cystectomy. Of these, 3083 patients (91.3%) were treated in 106 metropolitan ICUs and 293 patients (8.7%) were treated in 29 rural ICUs. There was no difference in adjusted mortality between metropolitan and rural hospitals admitted to an ICU after cystectomy (odds ratio 1.32, 95% confidence interval 0.44–3.48; P = 0.6).ConclusionThere was no difference in in‐hospital mortality for cystectomy patients requiring ICU admission between metropolitan and rural hospitals. These findings may be used to inform decisions about the rural provision of cystectomy services.
{"title":"Outcomes after cystectomy in Australian rural and metropolitan hospitals by intensive care admissions","authors":"Jessica A. Paynter, Zakary Doherty, Kirby R. Qin, David Pilcher, Janelle Brennan","doi":"10.1111/bju.16642","DOIUrl":"https://doi.org/10.1111/bju.16642","url":null,"abstract":"ObjectivesTo examine demographics and in‐hospital outcomes for patients admitted to Australian intensive care units (ICUs) following cystectomy of the urinary bladder. Additionally, to compare outcomes between metropolitan and rural hospitals.Patients and MethodsA retrospective cohort analysis was undertaken of all adult patients admitted to participating Australian ICUs (Australian and New Zealand Intensive Care Society Adult Patient Database) following cystectomy/cystoprostatectomy between January 2011 and December 2021. The primary outcome was in‐hospital mortality. Secondary outcomes were ICU and hospital length of stay.ResultsOver the 10‐year period, 3376 adult patients were admitted to 135 Australian ICUs after cystectomy. Of these, 3083 patients (91.3%) were treated in 106 metropolitan ICUs and 293 patients (8.7%) were treated in 29 rural ICUs. There was no difference in adjusted mortality between metropolitan and rural hospitals admitted to an ICU after cystectomy (odds ratio 1.32, 95% confidence interval 0.44–3.48; <jats:italic>P</jats:italic> = 0.6).ConclusionThere was no difference in in‐hospital mortality for cystectomy patients requiring ICU admission between metropolitan and rural hospitals. These findings may be used to inform decisions about the rural provision of cystectomy services.","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"30 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142987577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：